Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12092165 | 0.89 | USP2 (0.50) | GPR119EPHX2HPGDDDB1CRBN | |
| SCHEMBL310117 | 0.84 | GPR119 (0.67) | GPR119HPGDRECQLEPHX1 | |
| Formic Acid SCHEMBL31505515 | 0.84 | DDB1 (0.48) | GPR119EPHX2HPGDDDB1CRBN | |
| SCHEMBL4654454 | 0.83 | ITGB3 (0.40) | GPR119EPHX2EPHX1 | |
| SCHEMBL13274147 | 0.82 | GPR119 (0.65) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL8661760 | 0.81 | GPR119 (0.64) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL381974 | 0.80 | KDM4E (0.53) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL31621419 | 0.80 | SMN1; SMN2 (0.47) | EPHX2DDB1CRBN | |
| SCHEMBL28304217 | 0.79 | GPR119 (0.56) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL21359212 | 0.79 | EPHX1 (0.62) | GPR119HPGDRECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034444-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-10 | — | — | US | disclosed |
| US-7858622-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20100004228-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
| US-7579341-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-20070049581-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004228-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, CALCA | GPR119 176/4885EPHX2 2238/4885HPGD 406/4885 |
| US-20070049581-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | GPR119 176/4885EPHX2 2238/4885HPGD 406/4885 |
| US-20110034444-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, CALCA | GPR119 176/4885EPHX2 2238/4885HPGD 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.